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Abstract
Background
Operational research is required to design delivery of pre-exposure prophylaxis (PrEP) and
early antiretroviral treatment (ART). This paper presents the primary analysis of program-
matic data, as well as demographic, behavioural, and clinical data, from the TAPS Demon-
stration Project, which offered both interventions to female sex workers (FSWs) at 2 urban
clinic sites in South Africa.
Methods and findings
The TAPS study was conducted between 30 March 2015 and 30 June 2017, with the enrol-
ment period ending on 31 July 2016. TAPS was a prospective observational cohort study
with 2 groups receiving interventions delivered in existing service settings: (1) PrEP as part
of combination prevention for HIV-negative FSWs and (2) early ART for HIV-positive FSWs.
The main outcome was programme retention at 12 months of follow-up. Of the 947 FSWs
initially seen in clinic, 692 were HIV tested. HIV prevalence was 49%. Among those return-
ing to clinic after HIV testing and clinical screening, 93% of the women who were HIV-nega-
tive were confirmed as clinically eligible for PrEP (n = 224/241), and 41% (n = 110/270) of
the women who were HIV-positive had CD4 counts within National Department of Health
ART initiation guidelines at assessment. Of the remaining women who were HIV-positive,
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93% were eligible for early ART (n = 148/160). From those eligible, 98% (n = 219/224) and
94% (n = 139/148) took up PrEP and early ART, respectively. At baseline, a substantial frac-
tion of women had a steady partner, worked in brothels, and were born in Zimbabwe. Of
those enrolled, 22% on PrEP (n = 49/219) and 60% on early ART (n = 83/139) were seen at
12 months; we observed high rates of loss to follow-up: 71% (n = 156/219) and 30% (n = 42/
139) in the PrEP and early ART groups, respectively. Little change over time was reported
in consistent condom use or the number of sexual partners in the last 7 days, with high levels
of consistent condom use with clients and low use with steady partners in both study groups.
There were no seroconversions on PrEP and 7 virological failures on early ART among
women remaining in the study. Reported adherence to PrEP varied over time between 70%
and 85%, whereas over 90% of participants reported taking pills daily while on early ART.
Data on provider-side costs were also collected and analysed. The total cost of service deliv-
ery was approximately US$126 for PrEP and US$406 for early ART per person-year. The
main limitations of this study include the lack of a control group, which was not included due
to ethical considerations; clinical study requirements imposed when PrEP was not approved
through the regulatory system, which could have affected uptake; and the timing of the
implementation of a national sex worker HIV programme, which could have also affected
uptake and retention.
Conclusions
PrEP and early ART services can be implemented within FSW routine services in high prev-
alence, urban settings. We observed good uptake for both PrEP and early ART; however,
retention rates for PrEP were low. Retention rates for early ART were similar to retention
rates for the current standard of care. While the cost of the interventions was higher than
previously published, there is potential for cost reduction at scale. The TAPS Demonstration
Project results provided the basis for the first government PrEP and early ART guidelines
and the rollout of the national sex worker HIV programme in South Africa.
Author summary
Why was this study done?
• Female sex workers are a vulnerable population at risk of HIV, and, in some areas of
South Africa, nearly 3 out of 4 sex workers are already infected.
• Pre-exposure prophylaxis (PrEP) and early antiretroviral treatment (ART) are interven-
tions being piloted by national programmes to test whether (and how) they can be suc-
cessfully delivered in clinics and the public sector.
• We conducted a study in existing sex-worker-specific clinics to see if female sex workers
would take up and use PrEP and early ART if these interventions were offered. We part-
nered with the South African government to align and incorporate our results into
national HIV programming.
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What did the researchers do and find?
• We offered PrEP to HIV-negative female sex workers and early ART to HIV-positive
female sex workers in 2 clinics located in Johannesburg and Pretoria in South Africa.
Over time, we assessed how many women were contacted for the intervention, how
many came to the clinic for HIV testing, how many were HIV-negative and -positive,
and how many took up the interventions. We then monitored those who participated
for at least 12 months to see whether they stayed in the programme and used PrEP or
early ART.
• We found an HIV prevalence of 49% among the 692 women tested. Among those
returning to clinic after HIV testing and clinical screening, 93% were confirmed eligible
for PrEP, and 94% for early ART. From those eligible, 98% and 94% took up PrEP and
early ART, respectively. At the end of the 12-month assessment, 22% remained on
PrEP, while 60% remained on early ART, at our clinic sites. It is possible that some
women moved to other sites without our knowledge, as other sites started offering PrEP
and early ART.
• The drugs were safe to use with few side effects. We also found that women who stayed
in the study reported taking their pills regularly. None of the women who remained in
the study in the PrEP group got HIV, and very few women taking early ART had issues
supressing the virus. The overall cost of the programme came to approximately US$126
for PrEP and $406 for early ART per person-year.
What do these findings mean?
• These findings suggest that female sex workers may be interested in both PrEP and early
ART and that the interventions work well when taken, but longer term commitment
may be a challenge.
• These interventions have already been introduced by the South African government
into sex worker programmes, including those for male, female, and transgender people.
Introduction
Rates of new HIV infections remain high, especially in key populations in sub-Saharan Africa,
necessitating new options for HIV prevention and treatment [1,2]. Mathematical and clinical
studies suggest that a programme combining current HIV prevention options with oral pre-
exposure prophylaxis (PrEP), i.e., giving antiretrovirals to uninfected individuals, and early
antiretroviral treatment (ART), i.e., giving antiretrovirals to HIV-infected individuals irrespec-
tive of CD4 count, could make significant inroads on reducing new infections in key and gen-
eral populations [3–7].
Following the transition of WHO treatment guidelines to recommending both PrEP and
early ART, research has shifted focus to answering questions about implementation [5],
including uptake, adherence, and retention in existing programmes [8]. Demonstration proj-
ects, open-label extension studies, and population-based implementation trials testing feasibil-
ity in ‘real world’ settings are ongoing or have been recently completed [9,10]. Most of the
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completed demonstration projects have focused on men who have sex with men (MSM) popu-
lations throughout the world (though primarily in the United States, South America, and
Europe) [10]. One or two other projects have been completed among serodiscordant couples
[11], and only one randomised control trial implementation study had been completed among
female sex workers (FSWs) at the time of the writing of this report [12].
In South Africa, although sex work is still criminalised, FSWs have been prioritised for
focused, tailored services in the previous and new National Department of Health (NDoH)
national strategic plans for HIV, as well as a specialised plan for sex workers, as the population
with the highest incidence and prevalence of HIV, especially in urban areas [13–15]. The
national sex worker HIV programme includes support for demonstration projects to further
the development of specialised services including PrEP and early ART.
The TAPS (Treatment And Prevention for female Sex workers) Demonstration Project,
nested within the long-standing Sex Worker Programme (SWP) [16], was designed to support
integration of oral PrEP, as part of a combination prevention approach, and early ART into
existing HIV services in 2 urban settings, with specific aims to assess uptake, retention, and
adherence among FSWs and to estimate the cost of this strategy. TAPS was the first demon-
stration project in South Africa to include PrEP and early ART for FSWs, and among the first
few in sub-Saharan Africa as well. This paper presents the primary results.
Methods
The TAPS Demonstration Project was a prospective observational cohort designed as a real-
world implementation study to integrate PrEP, as part of a combination prevention approach,
and early ART into existing services for evaluation. The protocol has been described in detail
in a previous publication [17]. The TAPS Demonstration Project protocol was approved by
the University of the Witwatersrand Human Research Ethics Committee (reference number:
140502) and the South African Medicines Control Council (reference number: 20140740). All
participants completed a written informed consent process for the study consisting of a com-
prehensive consent form for the main study, as well as additional forms for laboratory sample
storage and the qualitative study components. Costing studies were also performed after secur-
ing consent from clinic staff.
Setting and intervention
TAPS was embedded within the SWP, operated by Wits Reproductive Health and HIV Insti-
tute, which is integrated into the South African public health clinical service. The SWP has
been in existence since 1996 and is run by nurses, community health workers, and peer educa-
tors [16]. Systematic formative research conducted to support the design and in preparation
for TAPS is presented elsewhere [18].
The 2 clinic sites were situated in inner-city Johannesburg and Pretoria. These clinics cater
to an urban population of sex workers working in hotel brothels, on streets, and in other infor-
mal environments. The clinics provide standard-of-care primary healthcare including HIV
testing services, male and female condom distribution, nurse-initiated and managed ART,
tuberculosis (TB) screening, contraceptive provision, cervical cancer screening, clinical ser-
vices for sexually transmitted infections (STIs) and minor ailments, psychosocial support, and
referrals for pregnancy and other clinical and legal services.
Recruitment of FSWs took place in the clinics and in surrounding brothels, bars, and
streets, relying on existing peer educator outreach services. Screening for participation was
conducted in 2 steps. First, women were tested for HIV using a standard-of-care rapid test.
This step included obtaining NDoH HIV testing service written consent and asking brief
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questions as to current pregnancy and whether they were a sex worker (e.g., they were asked to
self-identify after peer recruitment in their places of work). Women were then either referred
to other relevant care (if they were pregnant, were not a sex worker, or decided not to proceed)
or they continued on to clinical screening for the TAPS study. This process always occurred
on the same day to ensure that HIV testing and clinical assessments were aligned. The next
phase of the screening process began by obtaining study-specific written consent, then contin-
ued with the assessment of clinical history, administration of demographic and behavioural
questionnaires, TB and pregnancy screening, and blood draws for creatinine measurement,
hepatitis B screening, and syphilis testing. HIV status confirmation with ELISA was done for
HIV-positive participants at a private laboratory, where all the other samples were also ana-
lysed. Women were offered contraception, as well as advised of the need to use condoms to
prevent HIV, STIs, and unwanted pregnancies.
After screening, participants were asked to return a week later, to allow for laboratory anal-
yses to be completed, for potential enrolment into either PrEP for HIV-negative FSWs or early
ART for HIV-positive FSWs. The definition of early ART has evolved in line with national
guidelines. At the start of the study, the CD4 threshold for treatment initiation was 350 cells/
ml; the threshold changed to 500 cells/ml, and then treatment initiation became independent
of CD4 count during the course of the study. Since our purpose was to offer treatment to those
not eligible for ART under current guidelines, TAPS transitioned with the national treatment
initiation definition. Project milestones are provided in S1 Fig. Women were eligible for the
study if they were age 18 years or over, were not pregnant at enrolment, did not have multi-
drug-resistant TB, were not participating in another clinical study, and had finished their regi-
men for post-exposure prophylaxis if they were taking it at the time of assessment. Those who
became pregnant through the course of the study were given the option to remain in the study
on current medication, discontinue use during the period of pregnancy and remain in the
study, or transfer out completely to antenatal care. The first 2 options also included referrals to
antenatal care.
Once initiated on PrEP or early ART, participants were scheduled for an initial 1-month
check-in to assess safety and/or adherence issues, and then were scheduled for quarterly clini-
cal testing and safety monitoring visits thereafter. All clinical monitoring followed South Afri-
can national guidelines throughout the study (also detailed in the published protocol) [17],
and all services were provided free of charge as per the public health clinic standard, including
PrEP and early ART. Participants were given refills of 1–3 months depending on ability to
safely store the products and desire to come to the clinic for refills. The importance of consis-
tent and high adherence was emphasised for PrEP use; however, participants could cycle on
and off medication during periods of lower risk as desired and remain in the study. Indeed,
the PrEP intervention for HIV-negative women included not only the use of PrEP but also
other available prevention options (such as condoms, continuous testing and counselling, and
STI screening). Participants were offered short message service (SMS) reminders for clinic vis-
its and positive messaging around adherence, health, and psychosocial issues.
For both groups, participants were asked about pill-taking habits using a motivational tech-
nique at each staff touch point: counselling, clinical, and pharmacy. Counselling followed the
current standard of care for ART provision. Blood samples were taken for analysis of drug lev-
els in PrEP participants, the results of which will be presented at a later date as they are not cur-
rently available. Adverse events were recorded per Good Clinical Practice guidelines and
WHO recommended grading [19,20].
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Evaluation
Programmatic data to describe eligibility and uptake were collected in activity reports includ-
ing the number of outreach contacts and appointments booked. Routinely collected demo-
graphic, behavioural, and clinical data were also analysed. Retention in care at 12 months was
the primary outcome. Participants exited the analysis if they withdrew from the study or were
lost to follow-up, defined as no contact over 2 consecutive quarterly clinic visits or not com-
pleting an exit visit at 12 months. Participants were considered retained in the programme if
they had not withdrawn or been lost to follow-up during the 12-month period. We used an
adapted cascade approach to measure uptake and retention through a series of touch points
with participants. These points started during outreach and the enrolment process. Retention
data are reported at each of the time points (3, 6, 9 and 12 months). Women who missed visits
and returned later were included in the analysis. Data for those women who completed more
than 12 months of follow-up are included in S3 Text.
Data were analysed on self-reported adherence and sexual behaviour, STI diagnoses, and
occurrence of side effects. We also monitored any possible seroconversions on PrEP and viro-
logical failures on early ART. Qualitative research including in-depth interviews (with a selec-
tion of up to 10% of study participants), clinic observations, and group discussions with
providers was also conducted and will be presented separately.
Costs were estimated from a healthcare provider perspective for each clinic using an ingre-
dient approach. We included capital costs (equipment, buildings, non-recurrent training) as
well as recurrent costs (personnel, supplies, management, and maintenance of buildings). Cap-
ital costs were annualised. Data collection activities included measurement of clinic space,
completion of weekly timesheets by staff involved in the programme that detailed time per
programme activity versus research activities, observations of practice detailing all clinical
activities during participant visits, interviews with staff exploring time shared with other pro-
grammes, and review of expenditure and utilisation data with regards to the programme.
Sources used in the valuation of all resources, and methods for allocation of shared resources,
are detailed in Table A of S2 Text. We used both bottom-up and top-down approaches to cal-
culate unit cost per visit. Economic costs were assigned to drugs as per procurement prices
from NDoH for generics (US$4.8/month for PrEP; US$8.3/month for early ART); quantities
of drugs dispensed per patient were sourced from clinical and pharmacy records. Services,
activities, and healthcare providers involved in each type of visit are listed in Table B of S2
Text. We present unit costs for the different types of visits (outreach contact, testing session,
enrolment, follow-up, and refill visits). Our unit costs per person-year for PrEP and early ART
include enrolment, follow-up, and refill visits taking place during the first year of services and
reflect the attendance patterns observed during the TAPS Demonstration Project. All prices
were collected in local currency and are reported in 2015 US dollars. The average exchange
rate used was US$1 = R 11.6. All data were analysed in STATA 12 (StataCorp) and EXCEL
2016 (Microsoft).
A national programme including PrEP and early ART for FSWs was launched in June
2016, during the study, and may have influenced enrolment and retention. To test this, a strati-
fied analysis of uptake and retention indicators is provided in S3 Text, comparing the cascade
results among TAPS cohorts disaggregated by time of enrolment and follow-up period. We
tested the null hypothesis that the 2 proportions are the same at each step of the cascade and
report p-values for this testing. This analysis was the only additional analysis not prospectively
defined.
HIV treatment and prevention among female sex workers: A prospective observational demonstration project
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Results
Outreach and uptake
Enrolment for the TAPS study occurred between 30 March 2015 and 31 July 2016. The process
began with outreach and recruitment, by which 7,140 FSWs were contacted of the 10,548
names gathered across the 2 sites, after excluding duplicates and inaccurate phone numbers
(Fig 1). Contacts included women recorded on waiting lists leading up to the launch of the
study that were compiled during pre-study outreach and community education activities.
After making contact, a total of 947 FSWs were seen in the clinic, of which 692 were HIV
tested (73%) as per standard of care. At this point, 21% (n = 197) of the women were found to
be already taking ART, to be pregnant, or to not consider themselves to be sex workers,
Fig 1. Flowchart of participant enrolment and follow-up. ART, antiretroviral treatment; HepB+, hepatitis B positive; CD4 count<threshold, CD4 count
results below the threshold for ART initiation at the time of assessment; PrEP, pre-exposure prophylaxis.
https://doi.org/10.1371/journal.pmed.1002444.g001
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making them ineligible for enrolment. These women were referred to relevant care options,
and therefore did not complete the next phase of study screening, which occurred in the same
visit as the HIV testing. Among those tested for HIV, there was a prevalence of 49% (n = 341/
692). Following HIV testing, 79% (n = 241/351) and 69% (n = 270/341) participants returned
for enrolment for PrEP and early ART, respectively. Among the HIV-negative participants
who returned for eligibility assessment, 93% were assessed as clinically eligible for PrEP (n =
224/241). Among the HIV-positive participants who returned for eligibility assessment, 41%
(n = 110/270) had CD4 counts within NDoH ART initiation guidelines at assessment, and
93% of those remaining were eligible for early ART (n = 148/160). Reasons for non-eligibility
are presented in Fig 1. Uptake among those eligible was high: 98% (n = 219/224) of FSWs
offered PrEP accepted, and 94% (n = 139/148) of FSWs offered early ART accepted. At the end
of this process, 219 HIV-negative and 139 HIV-positive FSWs were enrolled. The detailed
numbers of participants at each step of enrolment and follow-up are presented in Table A of
S3 Text.
The comparison of TAPS cohorts, both PrEP and early ART, disaggregated by time of
enrolment (e.g., before or after the launch of the national sex worker HIV programme)
revealed no statistically significant differences throughout the enrolment and retention cas-
cade, aside from 2 points: number of appointments booked (20% of contacts made resulted in
an appointment being booked in the cohort enrolled before the national programme as
opposed to 26% among those enrolled after the programme launch) and number eligible for
early ART (more HIV-positive participants were eligible for early ART in the cohort recruited
after the programme launch, 95%, compared to the cohort enrolled before the programme
launch, 51%). In particular, the higher proportion of appointments booked from contacts
made among those enrolled in the cohort after the launch of the programme compared to
those enrolled before the programme could be related to larger recruitment and education
efforts at the sites. The higher proportion of participants eligible for early ART in the cohort
recruited after the programme started could be an indication of earlier presentation. The com-
parison of TAPS cohorts, both PrEP and early ART, disaggregated by completion of follow-up
period (e.g., 12-month follow-up completed before or after the launch of the national pro-
gramme) revealed no statistically significant differences throughout the enrolment and reten-
tion cascade. These results are presented in Table B of S3 Text. Further details regarding
enrolment statistics over time can be found in Fig C of S3 Text.
Baseline characteristics
In Table 1, selected baseline characteristics of enrolled participants are presented. Women
enrolled in the PrEP group were significantly younger than those enrolled in the early ART
group. In both groups, a substantial fraction of FSWs were currently in a steady partnership
(48% on early ART and 53% on PrEP), were born in Zimbabwe (48% on early ART and 67%
on PrEP), and had a secondary education (86% on early ART and 87% on PrEP). A substantial
majority of the participants worked in brothels: 62% in the early ART group and 77% in the
PrEP group.
Visit attendance and retention
During the first 12 months of follow-up, 156 and 42 participants (71% and 30%) were lost to
follow-up (missed 2 clinical monitoring visits or did not complete an exit visit at 12 months)
from the PrEP and early ART groups, respectively. The prevention and care cascades are
shown in Fig 2.
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The study follow-up period closed in 30 June 2017. In all, 22% and 60% of the enrolled
PrEP and early ART cohorts, respectively, attended the 12-month visit. Overall, programme
adherence was higher in the early ART group compared to the PrEP group, where participants
tended to be less regular in their attendance. This is illustrated graphically in Fig D of S3 Text.
Eight women withdrew, 4 from each group. Reasons for withdrawal were either side effects or
moving to another location. Extended cascade results for those women who attended the study
for a period of time longer than 12 months are presented in Table E of S3 Text. When examin-
ing loss to follow-up over time, as shown in Fig F of S3 Text, we observed that most women
dropped off earlier in the schedule, in particular in the PrEP group. Denominators for each
point in the cascade are also shown in Table E of S3 Text and should be taken into account for
the results regarding loss to follow-up over time shown in Fig F of S3 Text.
Table 1. Baseline characteristics of female sex worker participants enrolled (total n = 358).
Characteristic Detail Early ART (n = 139) PrEP (n = 219) p-Value*
n Percent, mean, or median n Percent, mean, or median
Age Mean (SD) 139 31.9 (6.4) 219 29.8 (5.9) 0.0016
Median (min–max) 31.7 (19.6–40.0) 28.9 (18.0–55.4)
Age group
18–20 years 1 0.7% 2 0.9% 0.001
21–30 years 53 38.1% 127 58.0%
31–40 years 71 51.1% 77 35.2%
41–50 years 14 10.1% 10 4.6%
51–60 years 0 — 3 1.4%
Current partnership No current partner 70 50.4% 102 46.6% 0.599
Single, no partners at present 64 46.0% 88 40.2%
Divorced or separated 5 3.6% 7 3.2%
Married and living apart 1 0.7% 7 3.2%
Currently in a steady partnership 67 48.2% 116 53.0%
Steady partner, not married/not living together 52 37.4% 85 38.8%
Steady partner, not married but living together 14 10.1% 24 11.0%
Married and living together 1 0.7% 7 3.2%
Did not answer 2 1.4% 1 0.5%
Country of origin Zimbabwe 67 48.2% 146 66.7% 0.009
South Africa 60 43.2% 60 27.4%
Lesotho 7 5.0% 10 4.6%
Swaziland 3 2.2% 1 0.5%
Mozambique 2 1.4% 2 0.9%
Education No education 0 0.0% 1 0.5% 0.107
Primary 15 10.8% 12 5.5%
Secondary 120 86.3% 189 86.3%
Tertiary 4 2.9% 15 6.9%
Did not answer/does not know 0 0.0% 2 0.9%
Place of work Hotel/brothel 86 61.9% 168 76.7% 0.008
Street 37 26.6% 28 12.8%
Home 4 2.9% 5 2.3%
Other 12 8.6% 18 8.2%
*All p-values are 2 sided; differences in means were assessed using t tests, and categorical variables were assessed using chi-squared tests.
ART, antiretroviral treatment; min, minimum; max, maximum; PrEP, pre-exposure prophylaxis.
https://doi.org/10.1371/journal.pmed.1002444.t001
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Secondary outcomes
In Fig 3, self-reported consistent condom use by partner type and study group is shown over
time. Higher condom use was reported with clients than with partners, especially main part-
ners (steady partners). Women on early ART appeared to use condoms slightly more with
casual and main partners than those on PrEP. Little change in reported condom use over time
by type of partner was observed. Additionally, there was no apparent increase in number of
partners over time. Further details on these data are presented in Table G in S3 Text. Number
of STI episodes at baseline and every 3 months are presented in Table H in S3 Text. As com-
pared with the number of episodes at study baseline, FSWs had significantly fewer STI epi-
sodes while participating in the study in both groups. These data are presented with the caveat
that dropout over time may contribute to bias in the numbers at later time points.
The proportion of women reporting taking PrEP pills daily varied over time between 70%
and 85%, whereas over 90% of participants reported taking pills daily while on early ART dur-
ing the first 12 months of follow-up (Table I in S3 Text).
During the first 12 months of follow-up, there were 7 pregnancies in the PrEP group: Three
women chose to terminate the pregnancy and continue on PrEP in the study, 3 were lost to
Fig 2. HIV prevention and care cascades. (A) HIV prevention cascade: pre-exposure prophylaxis cohort. (B) HIV treatment cascade: early antiretroviral
treatment cohort.
https://doi.org/10.1371/journal.pmed.1002444.g002
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follow-up, and 1 chose to continue on PrEP in the study while pregnant. There were 8 preg-
nancies in the early ART group, and an additional 4 in the extended follow-up period, 2 of
which were identified at study exit. All early ART participants chose to continue with the
study and their pregnancies.
One participant from the PrEP group who had previously decided to leave the study
returned after she became HIV-positive and was referred for ART initiation. In the early ART
group, there were 12 confirmed cases of virological failure—11 of which resulted in high-level
virological resistance to at least 1 drug (11 with resistance to efavirenz, 5 to emtricitabine, and
2 to tenofovir)—among the women retained in the study. One patient had fully susceptible
virus at resistance testing.
Of all 692 women who completed the screening process, only 1 participant presented with
serious complicating health issues, including suspected TB and a creatinine clearance of 50 ml/
min. There were no other cases presenting with creatinine clearance values outside of the
threshold for initiation of tenofovir.
PrEP and treatment drugs were well tolerated, with the majority of adverse events being
reported as mild for both groups, and few moderate. Of the 306 total adverse events recorded,
only 17 were assessed to be drug related: 8 women on PrEP reported mild headaches, nausea,
drowsiness, dizziness, or diarrhoea, and 9 women on early ART reported mild nausea, diar-
rhoea, dizziness, or drowsiness. One participant developed abnormal liver function tests, pre-
senting ill after taking early ART for 4 months. Liver function tests revealed severely abnormal
Fig 3. Sexual behaviour over time by partner type: consistent condom use and number of partners in last 7 days. (A) Consistent condom use: pre-
exposure prophylaxis cohort. (B) Number of partners in the last 7 days: pre-exposure prophylaxis cohort. (C) Consistent condom use: early antiretroviral
treatment cohort. (D) Number of partners in the last 7 days: early antiretroviral treatment cohort.
https://doi.org/10.1371/journal.pmed.1002444.g003
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liver function, and the woman was referred to a specialist, where the diagnosis was HIV-
induced sclerosing cholangitis.
Finally, in Table 2, both unit cost per visit type and overall cost of a person-year on early
ART and PrEP are shown. We found lower unit costs for the visit types involving low over-
heads, few drugs or tests (i.e., outreach visits), or less staff time (i.e., refill visits). The distribu-
tion of costs by input is presented in Fig J of S3 Text.
Discussion
In this prospective observational demonstration project, we observed high uptake of the PrEP
and early ART interventions among eligible FSWs. Retention in the early ART group was con-
sistent with the national programme [21], while retention in the PrEP group was lower at the
12-month assessment. There were few virological failures in the early ART group and no sero-
conversions in the PrEP group. However, given the low rate of retention at the end of the
study in the PrEP group, it is possible that women who dropped out and were not tracked
became HIV-positive. To our knowledge, this is the first demonstration project to present
results following the integration of a combined PrEP/early ART intervention into an existing
sex worker health programme. The results of this project supported the establishment of the
first official combined guidelines for oral PrEP and early ART in Africa, as well as the first spe-
cialised national programming including these interventions for sex workers in Africa [22,23].
The South African PrEP and early ART (or test and treat) guidelines were launched initially
for sex workers in June 2016, at which point PrEP and initiation of ART irrespective of CD4
count became standard of care for sex workers. Test and treat was then extended to all HIV-
positive people in South Africa in September 2016.
Additionally, TAPS has produced 2 important programmatic findings. First, the high num-
ber of women informed about the study translated into a much smaller number actually pre-
senting to take up the interventions. Since both PrEP and early ART are novel interventions in
this setting and for this population group, it is possible that as knowledge and use spread in
this community, overall uptake might increase, as seen with the introduction of contraception
[24]. Normalisation of new interventions may be key to their successful implementation [25],
and this will be explored further in the analysis of qualitative data. Second, among those who
presented at the clinic, there were high levels of intervention uptake for both PrEP and early
ART.
Table 2. Unit costs per visit and per person-year for PrEP and early ART among female sex workers (2015 US dollars).
Unit cost Site Mean
Johannesburg Pretoria
Outreach contact 3.0 2.6 2.8
VCT session 21.2 15.1 18.1
PrEP enrolment visit 40.4 29.0 34.7
PrEP monitoring visit 37.4 33.0 35.2
PrEP refill visit 7.4 6.2 6.8
PrEP per person-year, y1 146.6 106.6 126.6
Early ART enrolment visit 67.1 64.0 65.5
Early ART monitoring visit 72.5 62.9 67.7
Early ART refill visit 13.4 9.8 11.6
Early ART per person-year, y1 380.5 432.3 406.4
ART, antiretroviral treatment; PrEP, pre-exposure prophylaxis; VCT, voluntary counselling and testing; y1, initial year of services.
https://doi.org/10.1371/journal.pmed.1002444.t002
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The early ART group had a higher level of retention than the PrEP group. It is important to
note that retention in care refers to 2 different constructs depending on whether participants
are being retained in a prevention or treatment intervention. For the PrEP group, we formu-
lated our definition of retention to reflect maintenance of continuous contact with healthcare
services and access to prevention packages, even though the women were allowed to cycle in
and out of PrEP medication use. For the early ART group, we valued retention in care as an
essential component of a successful treatment programme. Interestingly, women who enrolled
on PrEP earlier in the study tended to be the ones who continued the longest, suggesting that
those most motivated, interested, and/or able to take up the interventions came earlier. It is
important to note that participants were not reimbursed for their participation, suggesting
that dedicated sex worker services can result in high levels of engagement in care among
FSWs.
We observed a significant participant drop-off between screening and assessment for eligi-
bility. Much of the loss may be directly related to the waiting period between screening and
enrolment required for research purposes and to assess laboratory results. This may not reflect
service delivery in future programmes where same-day initiation is being considered for both
PrEP and early ART. We had only a single creatinine case at screening meriting concern, and
immediate initiation of PrEP, with follow-up and potential discontinuation for those with con-
cerning results, may be possible.
Women who became pregnant in either study group were given options regarding main-
taining PrEP/ART use and staying in the study or transferring into other care. Of those who
continued on PrEP in the study, 1 woman continued her pregnancy, while 3 terminated their
pregnancies. It is possible that those who were lost to follow-up decided to see their pregnan-
cies through, but this is unconfirmed. It is also possible that by excluding those who were preg-
nant at enrolment, women highly motivated to take PrEP were not given the opportunity.
Given the heightened risk of HIV infection in women who become pregnant, being able to
continue PrEP use during pregnancy may be a critical programming consideration.
At baseline, the TAPS cohorts had similar demographic characteristics (age, education, and
place of origin) to the recently described local FSW population in Johannesburg [26]. Yet there
was a higher rate of FSWs in stable relationships in our sample. This is likely a reflection of the
group of FSWs accessing SWP clinics in general, as a similar profile was recently reported
among SWP attendees not enrolled in the study [27].
The patterns of visits to the clinic for PrEP combined with the reported adherence would
suggest intermittent use of PrEP while maintaining an overall engagement with services.
Although we only analysed self-reported adherence data in this paper, the data were collected
at every clinic and pill collection visit, and women did not report perfect adherence and usually
reported when they took ‘PrEP breaks’, suggesting a low level of social desirability bias. Addi-
tionally, with no seroconversions among the PrEP users, intermittent PrEP use does not
appear to be an issue in maintaining negative HIV status, noting also the high reported use of
condoms with clients. Reassuringly, there was no observed change over time in the study in
reported consistent condom use or number of partners in the last 7 days. There were fewer
STI episodes during the study than at baseline for both groups. This finding, combined with
the results of rigorous and consistent data collection on condom use over time with all sexual
partners, suggests that the women who remained in the study may have been improving their
attention to prevention through engagement in the study. This finding makes for an interest-
ing comparison with another completed demonstration project study among MSM, where
moderate increases in STIs during the study suggested slight reductions in condom use [28].
Finally, we estimated the total costs for PrEP and early ART per person-year to be in the
same order of magnitude as recently published estimates [29,30]. The higher TAPS costs for
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early ART compared to the costs included in the South African HIV and TB Investment Case
reflect the TAPS programme procedures, service utilisation, and staff costs, which are likely
higher than the costs of routine services [30].
Limitations
One limitation of the study is that no comparison group was included for either intervention,
limiting the ability to assess the effectiveness of integrated services, as it would not have been
ethical to maintain comparison groups with no or delayed access to interventions shown to be
effective [31]. A second limitation is that efforts to replicate healthcare delivery through an
integrated service were affected both by regulatory (dispensing from a pharmacy and medical
officer assessment of adverse events) and ethics committee (informed consent administration)
requirements. However, we expect that the removal of these requirements would improve
rates of uptake and retention.
In addition, a national PrEP and early ART programme for FSWs in South Africa started 1
June 2016. After its initiation, this programme could have influenced the uptake of the inter-
ventions for those FSWs approached for enrolment in TAPS. Conversely, it could have influ-
enced retention within the programme for those FSWs for whom the follow-up period
overlapped with the provision of the national programme. The TAPS clinics were the only pro-
viders of PrEP free of charge to FSWs in the public setting and required informed consent to
access the interventions as part of a research study, until the rollout of the national pro-
gramme, which also provided these services at no cost to clients. Furthermore, the implemen-
tation of PrEP as part of the national programme meant that PrEP could be viewed as the
standard of care and was therefore more normalised from the population’s perspective. Since
PrEP was no longer considered experimental after 31 May 2016, we expected that women
would think differently about PrEP, which could have affected uptake and retention in TAPS.
For example, as the programme was scaled up in the initial 11 sites (including in the 2 TAPS
sites), we became aware that some of the TAPS participants opted to collect their PrEP from
the mobile clinics in Pretoria, rather than coming to the fixed clinic where TAPS was located.
Finally, we do not have data on the women who did not come back to the study, and the
adherence and sexual behaviour data are self-reported, increasing the possibility of bias.
Unfortunately, drug level analyses in the PrEP group were not available at the time of writing.
These analyses will be presented in a more in-depth analysis in a subsequent publication.
Additionally, the data reported are based on populations of FSWs in 2 specific urban settings,
possibly limiting generalisability.
Conclusion
The findings from TAPS informed the setup of the national programme of PrEP and test and
treat for sex workers. This analysis shows that PrEP and early ART can be aligned with existing
health service programming for FSWs safely, without significant behaviour change, with high
rates of uptake for both interventions, and with expected cost reduction in routine settings at
scale.
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